BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol. 1999;31:215-220. [PMID: 10453932 DOI: 10.1016/S0168-8278(99)80216-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
2 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance. Gut Liver. 2009;3:108-115. [PMID: 20431732 DOI: 10.5009/gnl.2009.3.2.108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
3 Forrester JE, McGovern BH, Rhee MS, Sterling RK. The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population. HIV Med 2009;10:555-63. [PMID: 19496835 DOI: 10.1111/j.1468-1293.2009.00722.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Birk RZ, Rubinstein M. Leptin restores plasma cholesterol, glucose and weight loss induced by IFNalpha treatment. Biochem Biophys Res Commun 2007;355:626-31. [PMID: 17307134 DOI: 10.1016/j.bbrc.2007.01.197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol. 2006;12:7075-7080. [PMID: 17131467 DOI: 10.1111/j.1478-3231.2010.02365.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-6. [PMID: 17222321 DOI: 10.1111/j.1572-0241.2006.01038.x] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 12.3] [Reference Citation Analysis]
7 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
8 Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12(44): 7075-7080 [PMID: 17131467 DOI: 10.3748/wjg.v12.i44.7075] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 103] [Article Influence: 7.0] [Reference Citation Analysis]
9 Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431. [PMID: 16341948 DOI: 10.1007/s11096-005-1319-7] [Cited by in Crossref: 129] [Cited by in F6Publishing: 134] [Article Influence: 8.1] [Reference Citation Analysis]
10 Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B. Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocr Disord 2004;4:4. [PMID: 15555059 DOI: 10.1186/1472-6823-4-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]